FDA Approved NDA for Aficamten to Treat Patients With Obstructive Hypertrophic Cardiomyopathy

Source: Pharmacy Times articles

Aficamten, a cardiac myosin inhibitor, gains FDA approval, offering hope for improved cardiovascular health in patients with obstructive hypertrophic cardiomyopathy.
Read More